Oxilan

Last updated on RxList: 4/18/2017
Oxilan Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 04/19/2017

Oxilan (ioxilan injection) is a diagnostic radiopaque media used for cerebral arteriography, coronary arteriography and left ventriculography, visceral angiography, aortography, peripheral arteriography, excretory urography, and contrast enhanced computed tomographic (CECT) imaging of the head and body. Common side effects of Oxilan include:

The combination of volume and Oxilan concentration to be used should be carefully individualized accounting for factors such as age, body weight, size of the vessel and the rate of blood flow within the vessel. Oxilan may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Oxilan should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Oxilan (ioxilan injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Brain Food Pictures: What to Eat to Boost Focus See Slideshow
Oxilan Professional Information

SIDE EFFECTS

For demographics, see Clinical Trials section.

The following table of incidence of reactions is based upon controlled clinical studies in which OXILAN® was compared with a nonionic contrast agent (iohexol) in 531 patients. It includes all reported adverse events, regardless of attribution.

Adverse reactions are listed by body system and in decreasing order of occurrence greater than 0.5% in the OXILAN® group.

Body System Adverse Event Ioxilan (n=531) Comparator (n=542)
Body as a Whole Headache 19 (3.6%) 15 (2.8%)
Fever 9 (1.7%) 11 (2.0%)
Hematoma at Injection Site 4 (0.8%) 0 (0%)
Chills 3 (0.6%) 0 (0%)
Cardiovascular Angina Pectoris 7 (1.3%) 11 (2.0%)
Hypertension 6 (1.1%) 3 (0.6%)
Bradycardia 4 (0.8%) 0 (0%)
Hypotension 5 (0.9%) 3 (0.6%)
Digestive Nausea 8 (1.5%) 7 (1.3%)
Diarrhea 5 (0.9%) 4 (0.7%)
Nausea with Vomiting 5 (0.9%) 5 (0.9%)
Vomiting 3 (0.6%) 4 (0.7%)
Nervous Dizziness 4 (0.8%) 1 (0.2%)
Skin Urticaria 4 (0.8%) 4 (0.7%)
Rash 3 (0.6%) 4 (0.7%)

One or more adverse reactions were reported in 76 of 531 (14.3%) of patients in the clinical trials, coincidental with the administration of OXILAN® or within the study follow-up period of 24 to 72 hours. The incidence and type of adverse reactions were similar to those associated with the nonionic comparator (iohexol) used in the clinical trials. OXILAN®, as do other iodinated contrast agents, often causes warmth and/or pain on injection. The rates are similar to that of the iohexol comparator.

Serious, life threatening and fatal reactions have been associated with the administration of iodine-containing contrast media. In all clinical trials 3/835 (0.3%) patients given OXILAN® and 3/542 (0.6%) given iohexol died 4 days or later after drug administration. In the controlled trials 8/531 (1.5%) patients given OXILAN® and 6/542 (1.1%) given iohexol had serious adverse events.

The following adverse reactions were observed ≤ 0.5% of patients receiving OXILAN® Injection

BODY: allergic reaction, asthenia, chest and back pain, edema of the neck, facial edema, pain, peripheral edema; CARDIOVASCULAR: atrial fibrillation, syncope, tachycardia, vasodilation, ventricular extrasystole; DIGESTIVE: anorexia, constipation, dyspepsia, dysphagia, GI hemorrhage, ileus, liver failure; NERVOUS: hypotonia, nystagmus, paresthesia, somnolence, vertigo; RESPIRATORY: dyspnea, pharyngitis, rhinitis; SKIN: pruritus, sweating; SPECIAL SENSES: amblyopia, conjunctivitis, taste perversion, vision abnormality; UROGENITAL: anuria, dysuria, hematuria, infection of urinary tract, impairment of urination, kidney failure.

Additional adverse events reported in postmarketing surveillance with the use of OXILAN® Injection include: bronchospasm.

Read the entire FDA prescribing information for Oxilan (Ioxilan)

QUESTION

The abbreviated term ADHD denotes the condition commonly known as: See Answer

© Oxilan Patient Information is supplied by Cerner Multum, Inc. and Oxilan Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors